InMode (NASDAQ:INMD) Given New $33.00 Price Target at Barclays

InMode (NASDAQ:INMD) had its price objective lowered by investment analysts at Barclays from $34.00 to $33.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has an “overweight” rating on the healthcare company’s stock. Barclays‘s target price would indicate a potential upside of 84.15% from the stock’s current price.

INMD has been the topic of several other reports. UBS Group boosted their target price on InMode from $24.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 14th. Needham & Company LLC restated a “hold” rating on shares of InMode in a research note on Tuesday, April 9th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $32.80.

InMode Trading Down 3.0 %

Shares of NASDAQ INMD opened at $17.92 on Friday. The stock has a market capitalization of $1.50 billion, a PE ratio of 7.79 and a beta of 2.16. The stock’s fifty day simple moving average is $21.73 and its two-hundred day simple moving average is $22.38. InMode has a 12-month low of $17.74 and a 12-month high of $48.25.

InMode (NASDAQ:INMD) last posted its quarterly earnings data on Tuesday, February 13th. The healthcare company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. InMode had a return on equity of 29.80% and a net margin of 40.22%. The firm had revenue of $126.80 million during the quarter, compared to analysts’ expectations of $124.77 million. During the same quarter last year, the firm earned $0.69 EPS. The business’s quarterly revenue was down 5.1% on a year-over-year basis. On average, equities analysts predict that InMode will post 2.04 earnings per share for the current fiscal year.

Institutional Trading of InMode

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INMD. Exchange Traded Concepts LLC acquired a new position in shares of InMode in the 3rd quarter valued at about $27,000. Principal Securities Inc. acquired a new position in shares of InMode in the 4th quarter valued at about $32,000. Carmel Capital Partners LLC acquired a new position in shares of InMode in the 3rd quarter valued at about $36,000. Newbridge Financial Services Group Inc. acquired a new position in shares of InMode in the 3rd quarter valued at about $40,000. Finally, Brown Brothers Harriman & Co. acquired a new position in shares of InMode in the 1st quarter valued at about $41,000. Institutional investors and hedge funds own 68.04% of the company’s stock.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.